El interés en corto de Globus Medical da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Globus Medical. Los datos de interés en corto se actualizan cada dos semanas.

Globus Medical (NYSE:GMED) Bolsa, Informe de interés en corto

GLOBUS MEDICAL INC - A

Globus Medical

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

Pinterest,Mobile,App,On,The,Screen,Smartphone,Iphone,Closeup.,Pinterest

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CETY

CRVS

FIGS

GDOT

GMED

IOVA

JBIO

NCNA

PINS

PROF

SHPH

TMDX

VEEE

WOLF

WORX

ZKIN

Pinterest sube un 12,7 % tras superar ingresos del primer trimestre y aumentar usuarios mensuales. Otras acciones también reaccionan.

Acciones de Pinterest (PINS) se disparan un 13%; Aquí están 20 acciones que se mueven en el premercado

Short Ideas

OFIX

Orthofix Medical (OFIX) y Globus Medical (GMED) muestran niveles de RSI por encima de 70. ¿Es momento de vender?

¿Señal de alerta? Estas acciones de salud están sobrecompradas

Globus Medical, Inc. Class A Common Stock

Globus Medical Inc

Rio Tinto Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) shares are trading higher premarket on Monday after it finalized joint venture agreements with Sumitomo Metal Mining (SMM) to advance the Winu copper-gold project <a target="_blank" href="https://www.businesswire.com/news/home/20250511288741/en/Rio-Tinto-and-Sumitomo-Metal-Mining-sign-Definitive-Agreement-for-Winu-Project-joint-venture" rel="noreferrer noopener">in</a> Western Australia&#8217;s Great Sandy Desert.
According to the deal, Rio Tinto will remain responsible for the ongoing development and operation of the Winu project.
In return, Sumitomo Metal Mining will pay Rio Tinto up to $430.4 million for a 30% ownership stake in the project.
This includes an upfront payment of $195 million, with the potential for up to an additional $235.4 million in deferred payments contingent on achieving future project milestones.
Also Read: <a href="https://www.benzinga.com/news/management/25/05/45163353/rio-tinto-stops-activist-campaign-explores-critical-minerals-opportunities" target="_blank" rel="noreferrer noopener">Rio Tinto Stops Activist Campaign, Explores Critical Minerals Opportunities</a>
The transaction is anticipated to be finalized in 2025, pending regulatory approvals and standard closing conditions.
The Winu project, discovered by Rio Tinto in 2017, is described as an attractive, low-risk, long-life copper-gold deposit with significant potential for expansion beyond its initial development plans.
Rio Tinto is maintaining its focus on partnerships with the Nyangumarta and Martu Traditional Owners, including ongoing Project Agreement negotiations.
The pre-feasibility study for the Winu project, outlining an initial processing capacity of up to 10 million tonnes per annum (mtpa), is expected to be finalized in 2025.
Rio Tinto Copper Chief Executive Katie Jackson said, &#8220;Our relationship with SMM began in 2000 with our partnership at the Northparkes mine in New South Wales and we look forward to bringing our combined experience and expertise to deliver the Winu project.&#8221;
&#8220;This partnership is an excellent fit for Rio Tinto and will strengthen the project as we continue to prioritize the strong and enduring partnerships built to date with the land&#8217;s Traditional Owners, the Nyangumarta and the Martu.&#8221;
Last week, Rio Tinto disclosed that it entered into a Memorandum of Understanding (MoU) with&nbsp;AMG Metals &amp; Materials to explore the development of a large-scale,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/contracts/25/04/44869614/why-is-rio-tinto-betting-on-india-a-green-aluminium-gamble-could-reshape-supply-chains" rel="noreferrer noopener">low-carbon aluminum project in India</a>.
Investors can gain exposure to the stock via&nbsp;VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>) and iShares Copper and Metals Mining ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICOP#NASDAQ">ICOP</a>).
Price Action: RIO shares are up 2.90% to $61.72 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45163691/global-tensions-to-drive-a-two-year-copper-surplus-study-group-warns" target="_blank" rel="noreferrer noopener">Global Tensions To Drive Two-Year Copper Surplus, Study Group Warns</a></li>
</ul>
Image by Adwo via Shutterstock

Equities

Large Cap

Commodities

ICOP

Rio Tinto, Sumitomo Partner On $430 Million Copper-Gold Project In Australia

WIIM

Hut 8 shares are trading higher after the company announced that its subsidiary American Bitcoin will merge with Gryphon Digital.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">213.3300</td>
<td align="right">10.92</td>
<td align="right">5.39</td>
<td>49.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">226.7900</td>
<td align="right">9.19</td>
<td align="right">4.22</td>
<td>155.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.4399</td>
<td align="right">3.01</td>
<td align="right">3.65</td>
<td>179.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">140.2000</td>
<td align="right">4.09</td>
<td align="right">3.00</td>
<td>40.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.2100</td>
<td align="right">1.35</td>
<td align="right">2.70</td>
<td>890.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.6200</td>
<td align="right">2.06</td>
<td align="right">2.43</td>
<td>20.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">99.4600</td>
<td align="right">2.28</td>
<td align="right">2.34</td>
<td>4.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.2500</td>
<td align="right">0.64</td>
<td align="right">1.53</td>
<td>4.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.5201</td>
<td align="right">0.28</td>
<td align="right">0.34</td>
<td>67.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.9500</td>
<td align="right">0.04</td>
<td align="right">0.04</td>
<td>256.0K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">131.63</td>
<td align="right">-1.05</td>
<td align="right">-0.8</td>
<td>150.9K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For May 12, 2025

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Buy and lowers the price target from $18 to $15.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $15

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and lowers the price target from $8 to $7.

OCGN

HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $7

SLQT

SelectQuote shares are trading lower following Q3 financial results.

Canaccord Genuity analyst Jason Tilchen maintains Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) with a Buy and raises the price target from $12 to $14.

SGHC

Canaccord Genuity Maintains Buy on Super Group (SGHC), Raises Price Target to $14

PSNY

Polestar Automotive Holding shares are trading higher after the company reported a year-over-year increase in Q1 retail sales results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Steve Barger upgraded Federal Signal Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) from Sector Weight to Overweight and announced a $110 price target. Federal Signal shares closed at $89.56 on Friday. <a href="https://www.benzinga.com/quote/fss/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Argus Research analyst John Staszak upgraded the rating for Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from Hold to Buy and announced a $40 price target. Wayfair shares closed at $32.79 on Friday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Heckmann upgraded ACI Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIW#NASDAQ">ACIW</a>) from Neutral to Buy and maintained the price target of $60. ACI Worldwide shares closed at $46.56 on Friday. <a href="https://www.benzinga.com/quote/ACIW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz upgraded the rating for Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Hold to Buy and raised the price target from $226 to $303. Marriott International shares closed at $257.97 on Friday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Chris Schott upgraded Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from Neutral to Overweight and raised the price target from $21 to $23. Teva Pharmaceutical shares closed at $16.93 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying W stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-1024x584.png" alt="" class="wp-image-911884" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Upgrades

ACIW

TEVA

This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Guidance

UPLD

Upland Software Lowers FY2025 Sales Guidance from $231.50M-$255.50M to $209.50M-$227.50M vs $241.16M Est

New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function&nbsp;
Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits&nbsp;
SAN RAFAEL, Calif., May 12, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced new data from studies of VOXZOGO&#xAE;&nbsp;(vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal conditions. The data were presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) in Copenhagen, Denmark and will be shared at the Pediatric Endocrine Society Annual Meeting (PES) in National Harbor, Maryland.

BMRN

Biomarin Pharma Announces New VOXZOGO Data Showing Tibial Bowing Improvement In Achondroplasia

Upland Software Sees Q2 Sales $50.300M-$56.300M vs $61.17M Est

FTRE

Fortrea Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

<figure class="table"> 
<table>
<tbody>
<tr>
<td>Citizens &amp; Northern Corporation ("C&amp;N") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZNC#NASDAQ">CZNC</a>), headquartered in Wellsboro, Pennsylvania, and Susquehanna Community Financial, Inc. ("SQCF") (OTCPK: SQCF), headquartered in West Milton, Pennsylvania, announced today that both companies' boards of directors have unanimously approved an agreement and plan of merger (the "Agreement") pursuant to which SQCF will merge with and into C&amp;N. C&amp;N is the bank holding company for Citizens &amp; Northern Bank ("C&amp;N Bank"), which operates 28 banking offices and one loan production office in Pennsylvania and New York. As of March 31, 2025, C&amp;N had consolidated assets of $2.6 billion. SQCF is the financial holding company for Susquehanna Community Bank ("Susquehanna"), which operates 7 banking offices in Central Pennsylvania. SQCF had assets of $598 million as of March 31, 2025. In connection with the merger of the holding companies, SQCF's bank subsidiary, Susquehanna, will be merged into C&amp;N Bank. The combined company will have approximately $3.2 billion in assets and will be the premier Pennsylvania community bank in the northern tier, central and southeast Pennsylvania. This strategic combination represents a substantial extension of legacy C&amp;N markets, creating additional scale in central Pennsylvania, while enhancing C&amp;N Bank's capacity to provide exceptional service and solutions to its clients across the Commonwealth. In addition, C&amp;N will further diversify its loan portfolio and funding base, increasing its resiliency and efficiency. The combined entity will successfully align its core values to ensure best-in-class service to the Pennsylvania community. A joint announcement of the transaction was made today by J. Bradley Scovill, President and CEO of C&amp;N, and David S. Runk, Chief Executive Officer of SQCF. Mr. Scovill stated, "This combination continues our strategic efforts to enter attractive markets through acquisition and leverages the strengths of two reputable community banks that share a similar culture and customer-first mindset." He continued, "We believe this is a great fit and we are pleased to welcome Dave and the SQCF team and customers to C&amp;N as we work together to expand our presence in Central Pennsylvania."&nbsp; SQCF shareholders will receive 0.80 shares of C&amp;N common stock for each share of SQCF common stock held, which based on C&amp;N's most recent closing price implies a price per share of $15.58 or $44.3 million in total consideration. Holders of SQCF common stock prior to the consummation of the merger will own approximately 13% of C&amp;N's common stock outstanding immediately following the consummation of the merger. The merger is expected to be approximately ~17% accretive to earnings per share in 2026, while resulting in single-digit tangible book value dilution at close, demonstrating a strong balance of strategic growth and financial discipline. &nbsp;</td>
</tr>
</tbody>
</table>
</figure>

CZNC

Citizens & Northern To Acquire Susquehanna Community Financial In All-Stock Merger Valued At $44.3M, With SQCF Shareholders Receiving 0.80 C&N Shares Per SQCF Share

Earnings

Earnings Beats

Upland Software Q1 Adj. EPS $0.23 Beats $0.17 Estimate, Sales $63.66M Beat $61.17M Estimate

UPXI

Upexi shares are trading higher after the company announced it purchased 326,347 units of Solana to be the largest publicly traded Solana treasury company.

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) with a Buy and lowers the price target from $19 to $14.

Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $14

ORLA

Orla Mining shares are trading lower after the company reported worse-than-expected Q1 sales results.

Fueling R&amp;D of New Industrial Robots and Asia-Pacific Manufacturing Base Expansion
Shenzhen, China, May 12, 2025 (GLOBE NEWSWIRE) -- Lianhe Sowell International Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHSW#NASDAQ">LHSW</a>) (the "Company"), a provider of machine vision products and solutions applied in a wide range of businesses across industries in China, today announced it received a letter of intent (the "LOI") from a large investment fund in China, Hangzhou Yuhang Economic Development Equity Investment Fund (the "Fund"), for a funding of no more than RMB200 million. The Company plans to apply the investment primarily to support the R&amp;D of its next-generation industrial robots and the construction of the Company's manufacturing base in Hangzhou, Zhejiang province. The LOI is non-binding and the final investment terms will be subject to a definitive agreement between the Company and the Fund.

LHSW

Lianhe Sowell International Group Receives LOI From Hangzhou Yuhang Economic Development Equity Investment Fund For Funding Of No More Than RMB200 Mln

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $36 to $34.

RCKT

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $34

Press Releases

Globus Medical Reports Fourth Quarter and Full Year 2024 Results

Legal

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Nevro Corp. (NYSE – NVRO), 180 Degree Capital Corp. (Nasdaq – TURN)

Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference

Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting

Health Care

General

Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades

NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO

Comments

Globus Medical

Interés en corto

Globus Medical (NYSE:GMED) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL